Novartis' Enablex For Overactive Bladder Clears FDA

Enablex will enter a crowded overactive bladder market in early 2005 that includes two recent entrants, Yamanouchi/GlaxoSmithKline's Vesicare and Indevus/Pliva's Sanctura. Novartis may emphasize darifenacin's "unique" action on the M3 receptor to distinguish it from competitors.